Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc.
CHU de Reims
Suez Canal University
Suez Canal University
Suez Canal University
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Advanced Accelerator Applications
Taproot Health
Hutchmed
University Medical Center Groningen
Dana-Farber Cancer Institute
Roswell Park Cancer Institute
SCRI Development Innovations, LLC
Dana-Farber Cancer Institute
Radio Isotope Therapy of America
H. Lee Moffitt Cancer Center and Research Institute
Brahms AG
Ipsen
University of Iowa
Novartis
Amgen
Novartis
Novartis
University of Iowa
H. Lee Moffitt Cancer Center and Research Institute
Eli Lilly and Company
Novartis
Arbutus Biopharma Corporation
Centre Hospitalier Universitaire de Saint Etienne
H. Lee Moffitt Cancer Center and Research Institute
Dana-Farber Cancer Institute
Mateon Therapeutics
Novartis
Dana-Farber Cancer Institute
Virginia Commonwealth University
Columbia University
Vanderbilt-Ingram Cancer Center
Novartis
Dana-Farber Cancer Institute
Novartis
University of Western Ontario, Canada
H. Lee Moffitt Cancer Center and Research Institute
Novartis
Molecular Insight Pharmaceuticals, Inc.
Cylene Pharmaceuticals
CASI Pharmaceuticals, Inc.
Callisto Pharmaceuticals